Lobbying pays off for small drugmaker in budget bill
March 23, 2018
WASHINGTON (AP) — Tucked in the massive congressional budget bill is a provision that props up the price Medicare pays for a handful of medications, costing taxpayers millions at a time when the Trump administration is vowing to reduce the cost of prescription drugs.
Lawmakers acted after a lobbying campaign by a small Washington state pharmaceutical company called Omeros. Its main product is a drug called Omidria, used by hospitals in cataract surgery, which had recently lost a coveted Medicare reimbursement status. Individuals associated with the company also stepped up their political contr...
For access to this article please
sign in or
subscribe.
Reader Comments(0)